Stockscreener 앱 받기
49.05
0.08%
0.04
시간 외 거래:
49.40
0.35
+0.71%
전일 마감가:
$49.01
열려 있는:
$49
하루 거래량:
932.94K
Relative Volume:
0.31
시가총액:
$7.16B
수익:
$10.73M
순이익/손실:
$-455.74M
주가수익비율:
-13.79
EPS:
-3.5569
순현금흐름:
$-502.70M
1주 성능:
+1.91%
1개월 성능:
+19.46%
6개월 성능:
+71.98%
1년 성능:
+5.01%
1일 변동 폭
$48.25
$49.45
1주일 범위
$46.09
$51.79
52주 변동 폭
$21.51
$56.00
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
49.05 | 7.15B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.27 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
474.00 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.34 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
834.75 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.31 | 35.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Roth Capital | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
What momentum shifts mean for Avidity Biosciences Inc.Jobs Report & Daily Entry Point Alerts - newser.com
Ranking Avidity Biosciences Inc. among high performing stocks via toolsDip Buying & Fast Gain Stock Tips - newser.com
Avidity Biosciences Inc. stock daily chart insightsMarket Volume Report & Technical Analysis for Trade Confirmation - newser.com
Can Avidity Biosciences Inc. stock beat market expectations this quarterDividend Hike & Risk Controlled Daily Trade Plans - newser.com
How Avidity Biosciences Inc. stock compares to growth peersTrade Ideas & Verified Technical Trade Signals - newser.com
Avidity Biosciences, Inc. (RNA) Investor Outlook: Strong Buy Ratings Signal 42% Upside Potential - DirectorsTalk Interviews
Using R and stats models for Avidity Biosciences Inc. forecastingDollar Strength & Growth Focused Investment Plans - newser.com
Avidity Biosciences Inc. stock trendline breakdownJuly 2025 Opening Moves & Stock Market Timing Techniques - newser.com
Is Avidity Biosciences Inc. stock a top pick in earnings seasonShare Buyback & Low Drawdown Investment Strategies - nchmf.gov.vn
Aug Closing: Can Avidity Biosciences Inc. stock hit record highs again - nchmf.gov.vn
Aug EndMonth: Can Avidity Biosciences Inc. stock hit record highs againPortfolio Update Report & Reliable Price Action Trade Plans - nchmf.gov.vn
Is Avidity Biosciences Inc. stock a defensive play in 2025Market Activity Report & High Accuracy Investment Entry Signals - nchmf.gov.vn
Avidity Biosciences Insider Sold Shares Worth $1,003,058, According to a Recent SEC Filing - MarketScreener
Avidity Biosciences Executive Sells 20,000 Shares - TradingView
Avidity Biosciences Form 4: 20,000 options exercised at $22.34 - Stock Titan
How Avidity Biosciences Inc. stock performs in weak economyPortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Facioscapulohumeral Muscular Dystrophy Market Analysis Report 2025-2035: Innovations from Leading Players Such as Avidity Biosciences, F. Hoffman-La Roche, Epicrispr, and Fulcrum Fuel ExpansionResearchAndMarkets.com - The AI Journal
Will FDA Feedback and Del-Zota BLA Timeline Shift Redefine Avidity Biosciences' (RNA) Late-Stage Pipeline? - Yahoo Finance
Will a bounce in Avidity Biosciences Inc. offer an exitTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com
Is Avidity Biosciences Inc a good long term investmentRisk Management Strategies & Tap Into the Fastest-Growing Companies - earlytimes.in
Avidity reports positive pre-BLA meeting on Duchenne muscular dystrophy asset del-zota - MSN
Oct 21 panel: Avidity Biosciences to speak at Chardan Conference; webcast available 11:00 PT - Stock Titan
Avidity Biosciences to Participate in Upcoming Investor Conference - Sahm
Sector ETF performance correlation with Avidity Biosciences Inc.Trade Ideas & Weekly Top Gainers Trade List - newser.com
Forecasting Avidity Biosciences Inc. price range with options data2025 EndofYear Setup & High Return Stock Watch Alerts - newser.com
Avidity Biosciences Inc (RNA) Technical Analysis - TipRanks
What Makes Avidity Biosciences (RNA) an Investment Choice? - MSN
[8-K] – Avidity Biosciences, Inc. (RNA) (CIK 0001599901) | RNA SEC FilingForm 8-K - Stock Titan
Avidity Biosciences Delays Biologics License Application - TipRanks
Avidity Biosciences Updates BLA Submission Timeline for Del-Zota - TradingView
Avidity updates FDA filing plan; del-zota BLA now expected Q1 2026 - Stock Titan
Avidity Biosciences delays DMD drug submission to Q1 2026 By Investing.com - Investing.com Nigeria
Avidity rises on plans to submit muscle wasting drug application to US FDA - TradingView
Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission - MarketScreener
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 - Investing News Network
Avidity Biosciences delays DMD drug submission to Q1 2026 - Investing.com India
Avidity Biosciences announces positive pre-BLA meeting with US FDA for del-zota in DMD44 - MarketScreener
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.32%
1.34%
자본화:
|
볼륨(24시간):